InvestorsHub Logo
icon url

Dr Bala

05/18/21 9:08 PM

#378980 RE: Nick119 #378977

Thanks. Some slides look similar to the ones presented by LL at the University of Utah.
icon url

Dr Bala

05/18/21 9:11 PM

#378983 RE: Nick119 #378977

Nick or ATL, if you can attend the following talk by LL tomorrow and post some details, it should be great.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163890318

Unfortunately, the talk is at 5 AM my time, and I am usually on my way to work at that time.
icon url

FeMike

05/18/21 9:24 PM

#378991 RE: Nick119 #378977

Thanks Nick - can you expound on this?

I assume you’re referencing that her reference to an SAP with a primary endpoint of survival based on external controls can be correlated to benefit and thus ‘successful’. Clearly it represents Northwest’s new SAP. Anything else to be gleaned from this for us non-medical background folk?
icon url

Dan88

05/18/21 9:31 PM

#378998 RE: Nick119 #378977

Thank you very much Nick. I saw progressing of DCVax-L trial data analyses from LL's evolving data analyses.

Thank for the slide. It's assuring.
icon url

ATLnsider

05/18/21 10:49 PM

#379033 RE: Nick119 #378977

Thank you Nick119, i was glad to see the slide below because Dr. Linda Liau basically telegraphed and laid out how the the DCVax-L clinical trial data, and revised Primary Endpoint in the revised SAP will be analyzed.

According to the revised SAP, the new Primary Endpoint is as follows:

compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma. This endpoint will be assessed using 3 different analyses



Because of Dr. Liau's slide tonight, now we know what the 3 different analyses are:

Analysis 1: Cox Proportional Harzards

Analysis 2: Conditional Survival

Analysis 3: Subgroups, Cox PH



icon url

Margin Buu

07/01/21 9:03 PM

#387422 RE: Nick119 #378977

1:35-1:55

"..and it seems a shame that each time we have to do a large phase 3 trial we have to enroll several hundreds of more patients into these control arms, so over the next 10 years we will have another thousand patients in control arms just to prove that your new therapeutic actually works.."

Anytime we bring our hands in toward our heart or chest, we usually want to indicate to ourself. Looking down and to the right can indicate that the person speaking is attending to internal emotions.